Assertio Therapeutics (ASRT) Misses Q1 EPS by 9c

Assertio Therapeutics (NASDAQ: ASRT) reported Q1 EPS of ($0.14), $0.09 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $26.49 million versus the consensus estimate of $27.52 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.

You May Also Be Interested In

• Citi upgrades Bath & Body Works to Buy with $25 price target
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
• Pony AI (PONY) Reports Revenue Above Estimates